Search Patents
  • CORONAVIRUS VACCINES COMPOSITIONS AND METHOD OF USING SAME
    Publication number: 20230117744
    Abstract: The present disclosure provides compositions, for example vaccine compositions comprising live, attenuated coronavirus. The disclosure also provides methods of using coronavirus vaccines, including methods of treating and/or preventing coronavirus infections, and provides methods of preparing coronavirus vaccines.
    Type: Application
    Filed: March 23, 2021
    Publication date: April 20, 2023
    Inventors: Susan Baker, Xufang Deng, Kelly Milton Lager, Kay Faaberg, Alexandra DeVries
  • CORONAVIRUS VACCINE COMPRISING A MOSAIC PROTEIN
    Publication number: 20230256087
    Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.
    Type: Application
    Filed: January 19, 2023
    Publication date: August 17, 2023
    Inventor: Jorge E. OSORIO
  • CORONAVIRUS VACCINE THROUGH NASAL IMMUNIZATION
    Publication number: 20240123053
    Abstract: The invention generally discloses coronavirus vaccine for coronavirus disease. Particularly, the invention discloses coronavirus vaccine through nasal immunization. More particularly, the invention describes and develop a preventive vaccine against infection or disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through nasal immunization in mammals. Specifically, the invention describes human adenovirus which is engineered to express SARS-CoV-2 spike protein or part/fragment thereof which elicit immune response against the SARS-CoV-2 in mammals, and it is also suitable for immunizing human subjects. Describes the method of production of novel adenovirus vectors, use thereof in vaccine composition, vaccine formulation, preparation, and method of treatment of COVID-19 using above said novel vectors and compositions thereof.
    Type: Application
    Filed: May 7, 2021
    Publication date: April 18, 2024
    Applicant: BHARAT BIOTECH INTERNATIONAL LIMITED
    Inventors: Krishna Murthy ELLA, Krishna Mohan VADREVU, Raches ELLA, Raju SUNAGAR
  • Inactivated canine coronavirus vaccine
    Patent number: 4567042
    Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
    Type: Grant
    Filed: June 7, 1984
    Date of Patent: January 28, 1986
    Assignee: American Home Products Corporation
    Inventors: William M. Acree, Bobby Edwards, John W. Black
  • NOVEL CORONAVIRUS VACCINE BASED ON INFLUENZA VIRUS VECTOR AND PREPARATION METHOD THEREOF
    Publication number: 20230133364
    Abstract: Disclosed are a novel coronavirus vaccine based on an influenza virus vector and a preparation method thereof. The vaccine can efficiently express two antigens, i.e., its own HA antigen and an exogenous SC2R1 antigen, enabling the vaccine to induce immune responses to the two antigens, thus achieving the purpose of preventing both influenza virus and novel coronavirus, thereby eliminating the impacts of the two major infectious diseases of influenza and novel coronavirus on social economy, etc. at one time. In addition, based on existing mature influenza platform techniques, the influenza vaccine can be prepared and produced on a large scale, and the use of influenza vaccines has a long history and good safety.
    Type: Application
    Filed: August 25, 2021
    Publication date: May 4, 2023
    Inventors: Ling Chen, Lujie Han, Chenchen Yang, Qian Wang, Bo Liu
  • CORONAVIRUS VACCINE AND METHOD FOR PREPARATION THEREOF
    Publication number: 20240050557
    Abstract: The present invention relates to vaccine and treatment of novel coronavirus (SARS-CoV-2) infection (COVID-19) in mammals. Particularly, the invention relates to coronavirus vaccine and method for preparation thereof. More particularly, the present invention discloses preparation of coronavirus vaccine comprising an inactivated, purified SARS-CoV2 as active ingredient. The present invention also discloses a method for preparation of killed-inactivated SARS-CoV-2 virus which is used as antigen in the vaccine composition. The present invention further relates to the method of antigen preparation including inactivation and purification of virus, SARS-CoV-2 vaccine preparation, composition, formulation and use of the same to elicit immune response against the SARS-CoV-2 in mammals, and it is also suitable for immunizing human subjects.
    Type: Application
    Filed: August 21, 2021
    Publication date: February 15, 2024
    Applicant: BHARAT BIOTECH INTERNATIONAL LIMITED
    Inventors: Deepak KUMAR, Krishna Murthy ELLA
  • CORONAVIRUS VACCINE AND METHODS OF USE THEREOF
    Publication number: 20210393769
    Abstract: An immunogenic composition effective for eliciting an immune response against cells that present coronavirus S protein and/or coronavirus M protein derived antigens on a virus-like-particle (VLP) system. In a method embodiment, the antigen presenting VLP is administered to a mammal, such as a human, to elicit an immune response against coronavirus S protein and/or coronavirus M protein. A preferred method embodiment may include at least one additional dose of immunogenic composition to enhance the immune response effectiveness of the coronavirus vaccine.
    Type: Application
    Filed: June 8, 2021
    Publication date: December 23, 2021
    Inventor: Davinder Gill
  • Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus Vaccine
    Publication number: 20220090134
    Abstract: The present disclosure provides methods and compositions for enhancing immunity by administering a coronavirus vaccine and a chimeric CD40L polypeptide. The coronavirus vaccine can be comprised of inactivated coronaviral particles or an antigenic polypeptide, preferably the coronavirus spike protein. The coronavirus antigenic polypeptide can be a purified antigenic polypeptide or a nucleic acid expression construct that encodes the antigenic polypeptide. The chimeric CD40L polypeptide in compositions of the invention can be a purified chimeric CD40L polypeptide or a nucleic acid expression construction that encodes the chimeric CD40L polypeptide.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 24, 2022
    Applicant: Memgen, Inc.
    Inventor: Mark J. CANTWELL
  • CORONAVIRUS VACCINES AND USES THEREOF
    Publication number: 20230015616
    Abstract: This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.
    Type: Application
    Filed: November 30, 2020
    Publication date: January 19, 2023
    Inventors: Bill Biliang ZHANG, Man LI, Lin MA, Jian WEN, Hong ZHANG, Huiling ZHONG
  • DEVICE FOR MICROLITER-SCALE LYMPHATIC DELIVERY OF CORONAVIRUS VACCINES AND METHODS OF USE THEREOF
    Publication number: 20240090908
    Abstract: A fluid delivery device adapted for microliter-scale injections of coronavirus vaccines across a dermal barrier of a patient, for example to the lymphatic system of the patient, is described. The present disclosure also provides methods of administering coronavirus vaccines across a dermal barrier of a patient, for example to the lymphatic system of a patient.
    Type: Application
    Filed: January 21, 2022
    Publication date: March 21, 2024
    Inventors: Russell F. Ross, Henry Hongjun Ji
  • Live attenuated Coronavirus vaccines
    Publication number: 20060039926
    Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
    Type: Application
    Filed: May 23, 2005
    Publication date: February 23, 2006
    Inventor: Mark Denison
  • LARGE SEQUENCE PAN-CORONAVIRUS VACCINE COMPOSITIONS
    Publication number: 20230173060
    Abstract: Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CD8 T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).
    Type: Application
    Filed: October 14, 2022
    Publication date: June 8, 2023
    Inventor: Lbachir BenMohamed
  • Live attenuated coronavirus vaccines
    Patent number: 7452542
    Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: November 18, 2008
    Assignee: Vanderbilt University
    Inventor: Mark Denison
  • Anti-coronavirus vaccine
    Publication number: 20050053622
    Abstract: The invention relates to a vaccine against coronavirus infections and, in particular, against feline infectious peritonitis (FIP). The inventive vaccine comprises immunogenic peptides included in the S protein of feline coronaviruses (FcoV), which do not result from immunologic enhancement. The invention also relates to the use of at least one peptide for the preparation of a vaccine that induces protection against coronavirus infections, said peptide being selected from the group comprising fragments of an S protein of coronavirus of at least 12 amino acids, included in the SEQ ID NO: 5, or nucleic acid fragments of at least 36 nucleotides, included in the SEQ ID NO: 10 and coding for one of said peptides.
    Type: Application
    Filed: August 9, 2002
    Publication date: March 10, 2005
    Inventors: Andre Aubert, Veronique Duquesne, Marc Eloit, Valerie Gonon
  • CORONAVIRUS VACCINE
    Publication number: 20210322541
    Abstract: Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 21, 2021
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Jonathan F. SMITH, Ryuji UENO
  • MULTI-EPITOPE PAN-CORONAVIRUS VACCINE COMPOSITIONS
    Publication number: 20230146932
    Abstract: Multi-epitope, pan-coronavirus recombinant vaccine compositions featuring a combination of highly conserved B cell epitopes, highly conserved CD4+ T cell epitopes, and highly conserved CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The present invention uses several immuno-informatics and sequence alignment approaches and multiple immunological assays in vitro using human blood and saliva samples from COVID patients and healthy patients to identify several human B cells, CD4+ and CD8+ T cell epitopes that are highly conserved and antigenic in vitro. The Invention also used an in vivo unique mouse model of ACE2/HLA-A0201/HLA-DR triple transgenic mouse model to test the immunogenicity and the protective efficacy against SARS-CoV-2 infection and COVID-Like symptoms, of the identified B and T cell epitopes and of the resulting multi-epitope-pan-Coronavirus vaccine candidates.
    Type: Application
    Filed: October 14, 2022
    Publication date: May 11, 2023
    Inventor: Lbachir BenMohamed
  • SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES
    Publication number: 20230323389
    Abstract: Disclosed are synthetic modified vaccinia ankara (MVA)-based vaccines for preventing or treating coronavirus infections and methods of producing the vaccines. Specifically, the disclosure provides a vaccine composition comprising: (i) a single synthetic DNA fragment or two or more synthetic DNA fragments comprising the entire genome of an MVA, and (ii) one or more DNA sequences encoding one or more coronavirus antigens, subunits, or fragments thereof, inserted in one or more insertion sites of the MVA for preventing or treating coronavirus infections.
    Type: Application
    Filed: May 17, 2021
    Publication date: October 12, 2023
    Applicant: CITY OF HOPE
    Inventors: Don J. DIAMOND, Felix WUSSOW, Flavia CHIUPPESI
  • CORONAVIRUS VACCINE
    Publication number: 20230270841
    Abstract: The invention relates to vaccines, and in particular, to vaccines for preventing, treating or ameliorating coronavirus infections, such as severe acute respiratory syndrome coronavirus (SARS), SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS). The invention is especially concerned with self-amplifying RNA replicons and genetic constructs or vectors encoding such RNA replicons, and their use in vaccine delivery for preventing infections of coronavirus. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.
    Type: Application
    Filed: March 26, 2021
    Publication date: August 31, 2023
    Applicant: Imperial College Innovations Limited
    Inventors: Robin Shattock, Paul McKay, Anna Blakney
  • VARIANT STRAIN-BASED CORONAVIRUS VACCINES
    Publication number: 20240139309
    Abstract: The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 2, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Andrea Carfi, Guillaume Stewart-Jones, Hamiltion Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
  • VARIANT STRAIN-BASED CORONAVIRUS VACCINES
    Publication number: 20240100151
    Abstract: The disclosure provides coronavirus mRNA vaccines, including vaccines directed against one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
    Type: Application
    Filed: January 14, 2022
    Publication date: March 28, 2024
    Applicant: Moderna TX, Inc.
    Inventors: Andrea Carfi, Guillaume Stewart-Jones, Hamilton Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
Narrow Results

Filter by US Classification